Watanabe Todd sold $139K of ARQT

Watanabe Todd (See Remarks) sold 4,377 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $31.86 ($0.14M total) on 2026-11-02.

Original reporting
SEC EDGAR · Watanabe Todd
Published Nov 4, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Bearish
high confidence
Mentioned
$ARQT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTBearishLow
01

Why it matters

A modest insider sell that may cause short‑term pressure but is unlikely to affect long‑term valuation.

02

Market read

Primary disclosure of a small insider sale; limited trading relevance.

03

What to watch

Potential tax planning or liquidity needs of the insider, not necessarily a bearish signal.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑11‑02

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ARQTBearishHigh confidence
Context

Officer/director Watanabe Todd sold 4,377 shares at $31.86 each, total $139,466, reducing his stake to 712,826 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

Form 4 is a primary source; the transaction amount is small relative to market cap, so impact is limited.

Market effects

Minimal effect on the broader biotech sector; insider activity is routine.

US equity market, limited to ARQT shareholders.

Low

Counterpoint

The sale may be unrelated to company fundamentals and could be a routine portfolio rebalancing.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Biopharma developing dermatology treatments, ticker ARQT.

  • Watanabe Todd

    Officer and director of Arcutis Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.